197 related articles for article (PubMed ID: 15118259)
1. [Pharmacological and pharmacokinetic features and clinical effects of pitavastatin (Livalo Tablet)].
Yamazaki H; Fujino H; Kanazawa M; Tamaki T; Sato F; Suzuki M; Kitahara M
Nihon Yakurigaku Zasshi; 2004 May; 123(5):349-62. PubMed ID: 15118259
[TBL] [Abstract][Full Text] [Related]
2. Pitavastatin: an overview.
Saito Y
Atheroscler Suppl; 2011 Nov; 12(3):271-6. PubMed ID: 22152281
[TBL] [Abstract][Full Text] [Related]
3. Pitavastatin calcium: clinical review of a new antihyperlipidemic medication.
Yee LL; Wright EA
Clin Ther; 2011 Aug; 33(8):1023-42. PubMed ID: 21816477
[TBL] [Abstract][Full Text] [Related]
4. Pitavastatin: efficacy and safety profiles of a novel synthetic HMG-CoA reductase inhibitor.
Kajinami K; Takekoshi N; Saito Y
Cardiovasc Drug Rev; 2003; 21(3):199-215. PubMed ID: 12931254
[TBL] [Abstract][Full Text] [Related]
5. Are all statins the same? Focus on the efficacy and tolerability of pitavastatin.
da Silva PM
Am J Cardiovasc Drugs; 2011; 11(2):93-107. PubMed ID: 21446776
[TBL] [Abstract][Full Text] [Related]
6. Pitavastatin for the treatment of primary hyperlipidemia and mixed dyslipidemia.
Gotto AM; Moon J
Expert Rev Cardiovasc Ther; 2010 Aug; 8(8):1079-90. PubMed ID: 20670185
[TBL] [Abstract][Full Text] [Related]
7. Pitavastatin: novel effects on lipid parameters.
Chapman MJ
Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
[TBL] [Abstract][Full Text] [Related]
8. Pitavastatin: a new HMG-CoA reductase inhibitor.
Wensel TM; Waldrop BA; Wensel B
Ann Pharmacother; 2010 Mar; 44(3):507-14. PubMed ID: 20179258
[TBL] [Abstract][Full Text] [Related]
9. NK-104: a novel synthetic HMG-CoA reductase inhibitor.
Kajinami K; Mabuchi H; Saito Y
Expert Opin Investig Drugs; 2000 Nov; 9(11):2653-61. PubMed ID: 11060827
[TBL] [Abstract][Full Text] [Related]
10. Critical appraisal of the role of pitavastatin in treating dyslipidemias and achieving lipid goals.
Saito Y
Vasc Health Risk Manag; 2009; 5():921-36. PubMed ID: 19997573
[TBL] [Abstract][Full Text] [Related]
11. Pitavastatin.
Mukhtar RY; Reid J; Reckless JP
Int J Clin Pract; 2005 Feb; 59(2):239-52. PubMed ID: 15854203
[TBL] [Abstract][Full Text] [Related]
12. Place of pitavastatin in the statin armamentarium: promising evidence for a role in diabetes mellitus.
Kawai Y; Sato-Ishida R; Motoyama A; Kajinami K
Drug Des Devel Ther; 2011; 5():283-97. PubMed ID: 21625418
[TBL] [Abstract][Full Text] [Related]
13. Pitavastatin - pharmacological profile from early phase studies.
Catapano AL
Atheroscler Suppl; 2010 Dec; 11(3):3-7. PubMed ID: 21193152
[TBL] [Abstract][Full Text] [Related]
14. Pitavastatin: a new HMG-CoA reductase inhibitor for the treatment of hypercholesterolemia.
Ahmad H; Cheng-Lai A
Cardiol Rev; 2010; 18(5):264-7. PubMed ID: 20699675
[TBL] [Abstract][Full Text] [Related]
15. The clinical impact of pitavastatin: comparative studies with other statins on LDL-C and HDL-C.
Teramoto T
Expert Opin Pharmacother; 2012 Apr; 13(6):859-65. PubMed ID: 22332608
[TBL] [Abstract][Full Text] [Related]
16. Pitavastatin therapy in polymedicated patients is associated with a low risk of drug-drug interactions: analysis of real-world and phase 3 clinical trial data.
Gosho M; Tanahashi M; Hounslow N; Teramoto T
Int J Clin Pharmacol Ther; 2015 Aug; 53(8):635-46. PubMed ID: 26104032
[TBL] [Abstract][Full Text] [Related]
17. Lipid-lowering and antiatherosclerotic effect of NK-104, a potent 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in Watanabe heritable hyperlipidemic rabbits.
Suzuki H; Yamazaki H; Aoki T; Kojima J; Tamaki T; Sato F; Kitahara M; Saito Y
Arzneimittelforschung; 2000 Nov; 50(11):995-1003. PubMed ID: 11187394
[TBL] [Abstract][Full Text] [Related]
18. Pitavastatin: a review of its use in the management of hypercholesterolaemia or mixed dyslipidaemia.
Duggan ST
Drugs; 2012 Mar; 72(4):565-84. PubMed ID: 22356292
[TBL] [Abstract][Full Text] [Related]
19. Pleiotropic effects of pitavastatin.
Davignon J
Br J Clin Pharmacol; 2012 Apr; 73(4):518-35. PubMed ID: 22053916
[TBL] [Abstract][Full Text] [Related]
20. Combination therapy with pemafibrate (K-877) and pitavastatin improves vascular endothelial dysfunction in dahl/salt-sensitive rats fed a high-salt and high-fat diet.
Yoshida M; Nakamura K; Miyoshi T; Yoshida M; Kondo M; Akazawa K; Kimura T; Ohtsuka H; Ohno Y; Miura D; Ito H
Cardiovasc Diabetol; 2020 Sep; 19(1):149. PubMed ID: 32979918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
